|- candidate number||14290|
|- NTR Number||NTR3843|
|- ISRCTN||ISRCTN wordt niet meer aangevraagd.|
|- Date ISRCTN created|
|- date ISRCTN requested|
|- Date Registered NTR||5-feb-2013|
|- Secondary IDs||43405 ABR|
|- Public Title||Effect of amitriptyline in functional heartburn.|
|- Scientific Title||Effect of amitriptyline in functional heartburn.|
|- hypothesis||Amitriptyline ameliorates heartburn complaints in functional heartburn patients by modulating visceral perception.|
|- Healt Condition(s) or Problem(s) studied||Functional heartburn|
|- Inclusion criteria||1. Minimum age: 18 years;|
2. Documented functional heartburn:
A. Negative esophagogastroduodenoscopy and no history of reflux esophagitis;
B. Negative 24h pH/impedance recording (physiological acid exposure time) and negative symptom association probability.
|- Exclusion criteria||1. Surgery of the esophagus;|
2. Motility disorders of the GI tract leading to delayed gastric emptying or altered intestinal motility;
3. Use of any medication with a potential effect on upper gastrointestinal motility and/or sensitivity that can not be stopped for the duration of the study. If this medication can be stopped, it should be discontinued for at least 2 weeks before the start of the study;
4. Severe and clinically unstable concomitant disease (e.g. liver, cardiovascular or lung disease, neurological or psychiatric disorders, cancer or AIDS and other endocrine disorders);
5. Pregnancy or lactation. A pregnancy test will be carried out prior to inclusion in the study. Female patients who are premenopausal and have a negative pregnancy test should be on an anticonceptive;
A. Contra-indications for amitriptyline use: epilepsy, organic central nervous system disorders, prostate hypertrophy, pyloric stenosis, cardiovascular disease, hyperthyroidism, liver- and kidney function impairment;
B. Interaction can occur with barbiturates, carbamazepine, ketoconazol and ritonavir . Concommitant use of MAO-inhibitors is contra-indicated.
7. Hypersensitivity to the active substance or to any of the excipients.
|- mec approval received||yes|
|- multicenter trial||no|
|- Type||2 or more arms, randomized|
|- planned startdate ||1-mei-2013|
|- planned closingdate||1-mei-2015|
|- Target number of participants||21|
|- Interventions||Amitriptylin 25-50 mg daily or placebo for 6 weeks in a crossover design.|
|- Primary outcome||Esophageal sensitivy to acid perfusion (perfusion-related symptom score).|
|- Secondary outcome||1. Time to symptoms during esophageal acid exposure;|
2. Symptom severity during esophageal acid exposure (visual analog scale or VAS);
3. GERD symptom score improvement after an 8 week treatment with amitriptyline (GERDQ questionnaire, RDQ questionnaire, SF-LDG questionnaire);
4. Quality of life assessment (GERD-QoL questionnaire);
5. Psychological state and anxiety assessment (HADS and SF12 questionnaire).
|- Timepoints||6 and 20 weeks after start of compound.|
|- Trial web site||N/A|
|- CONTACT FOR PUBLIC QUERIES||Dr. A.J. Bredenoord|
|- CONTACT for SCIENTIFIC QUERIES||Dr. A.J. Bredenoord|
|- Sponsor/Initiator ||Academic Medical Center (AMC)|
(Source(s) of Monetary or Material Support)
|Academic Medical Center (AMC)|
|- Brief summary||Many of the patients presenting with typical reflux symptoms who do not respond to the current standard of care (i.e. proton pump inhibition), do not have gastro-esophageal reflux disease. Functional heartburn is an important differential diagnosis in this respect, and can be confirmed or excluded by performing a 24h pH/impedance recording: patients with functional heartburn do not have pathological acid reflux and the symptom-reflux association analysis is typically negative.
The management of functional heartburn is often challenging as evidence-based pharmacological options are not available. The use of visceral pain modulators such as tricyclic antidepressants is generally accepted, even though the clinical trials to support their use are likewise lacking.
The aim of the current trial is to validate the use of amitriptylin in functional heartburn and to study its mechanism of action.|
|- Main changes (audit trail)|
|- RECORD||5-feb-2013 - 16-feb-2013|